StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals EYLEA (2 mg) U.S. Net Product Sales YoY Growth by Quarter

EYLEA (2 mg) U.S. Net Product Sales YoY Growth (%) (%)

Regeneron Pharmaceuticals EYLEA (2 mg) U.S. Net Product Sales YoY Growth: -41.0% in Q3 2026, unchanged from a year earlier.

Latest, Q3 2026
-41.0%
Period ended Sep 30, 2026
Change on a year earlier
0.0 pts
-41.0% in Q3 2025
History
17 quarters
Since Q3 2022
Sources
17
Documents cited below

Where the Q3 2026 figure comes from

“Release Narrative Revenues (FY2026Q3): EYLEA ® - U.S. | 400 | 681 | (41 | %)”

Source: Form 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗

Reported in Form 8-K (EX-99.1) Financial Results — Revenues Narrative Table.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEYLEA (2 mg) U.S. Net Product Sales YoY Growth (%) (%)Year on yearSource
Q3 2026Sep 30, 2026-41.0%0.0 ptsForm 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗
Q2 2026Jun 30, 2026-45.0%-6.0 ptsForm 8-K (exhibit991q22026.htm, filed 2026-07-30) ↗
Q1 2026Mar 31, 2026-36.0%+3.0 ptsForm 8-K (exhibit991q12026.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 2025-52.0%-41.0 ptsForm 8-K (exhibit991q42025.htm, filed 2026-01-30) ↗
Q3 2025Sep 30, 2025-41.0%-20.0 ptsForm 8-K (exhibit991q32025.htm, filed 2025-10-28) ↗
Q2 2025Jun 30, 2025-39.0%-21.0 ptsForm 8-K (exhibit991q22025.htm, filed 2025-08-01) ↗
Q1 2025Mar 31, 2025-39.0%-23.0 ptsForm 8-K (exhibit991q12025.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 2024-11.0%0.0 ptsForm 8-K (exhibit991q42024.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024-21.0%-10.0 ptsForm 8-K (exhibit991q32024.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 2024-18.0%-11.0 ptsForm 8-K (exhibit991q22024.htm, filed 2024-08-01) ↗
Q1 2024Mar 31, 2024-16.0%-10.0 ptsForm 8-K (exhibit991q12024.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 2023-11.0%-8.0 ptsForm 8-K (exhibit991q42023.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-11.0%-22.0 ptsForm 8-K (exhibit991q32023.htm, filed 2023-11-02) ↗
Q2 2023Jun 30, 2023-7.0%–Form 8-K (exhibit991q22023.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023-6.0%–Form 8-K (exhibit991q12023.htm, filed 2023-05-04) ↗
Q4 2022Dec 31, 2022-3.0%–Form 8-K (exhibit991q42022.htm, filed 2023-02-03) ↗

Cite this data

StockData. (2026). Regeneron Pharmaceuticals EYLEA (2 mg) U.S. Net Product Sales YoY Growth (%), quarterly Q3 2022–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-eylea-2mg-us-yoy

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?